{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021960","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.715345+00:00","generated_at":"2026-06-24T02:08:41.391870+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China","bullets":["Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.","Cash position $1.26B; NMPA accepted BLA for efgartigimod in generalized myasthenia gravis.","Karuna's KarXT Phase 3 EMERGENT-2 met primary endpoint: 9.6-point PANSS reduction vs placebo (p<0.0001).","Josh Smiley appointed COO effective Aug 1; John Diekman named Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021960","json":"https://secwatch.observer/filing/0001628280-22-021960.json","markdown":"https://secwatch.observer/filing/0001628280-22-021960.md","text":"https://secwatch.observer/filing/0001628280-22-021960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/0001628280-22-021960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/zlab-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:08:41.391870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}